HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) |
| Excepted Quantity | USD 0.00 |
| Limited Quantity | USD 15-60 |
| Inaccessible (Haz class 6.1), Domestic | USD 80+ |
| Inaccessible (Haz class 6.1), International | USD 150+ |
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ |
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ |


| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | Autophagy ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI-0206965 |
+++
ULK2, IC50: 711 nM ULK1, IC50: 108 nM |
95% | |||||||||||||||||
| Hydroxychloroquine sulfate | ✔ | 99% | |||||||||||||||||
| Valproic acid sodium | ✔ | HDAC | 97% | ||||||||||||||||
| PFK-015 |
++
PFKFB3, IC50: 207 nM |
99%+ | |||||||||||||||||
| MRT68921 HCl |
++++
ULK2, IC50: 1.1 nM ULK1, IC50: 2.9 nM |
99%+ | |||||||||||||||||
| ROC-325 | ✔ | 99%+ | |||||||||||||||||
| Autophinib |
+++
Autophagy, IC50: 40 nM |
99% | |||||||||||||||||
| Lys05 | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 描述 | Lanatoside C, a cardiac glycoside, is utilized in the management of congestive heart failure and cardiac arrhythmias. It demonstrates an IC50 of 0.19 μM against dengue virus in HuH-7 cells and is capable of inhibiting all four serotypes of dengue virus, as well as flavivirus Kunjin, alphavirus Chikungunya, Sindbis virus, and human enterovirus 71[1].[2]. |
| 体外研究 | Lanatoside C shows a dose-dependent reduction in both dengue viral RNA and protein synthesis with increased concentrations. Studies on the timing of addition reveal that Lanatoside C blocks the early stages of the dengue virus replication cycle. Additionally, it effectively inhibits all four dengue virus serotypes, flavivirus Kunjin, alphavirus Chikungunya, and Sindbis virus, along with human enterovirus 71, displaying a broad-spectrum antiviral activity against various positive-sense RNA viruses[2]. |
| Concentration | Treated Time | Description | References | |
| Jurkat cells | 2 μM | 6 hours | Lanatoside C significantly downregulated RUNX1 protein level | EMBO Mol Med. 2025 Mar;17(3):563-588 |
| Gli36 cells | 0.25 μM | 48 hours | Lanatoside C enhances Gli36 cell sensitivity to TRAIL. | Neuro Oncol. 2011 Nov;13(11):1213-24 |
| HF19 primary human fibroblasts | 0.25 μM | 48 hours | Lanatoside C shows no significant toxicity to normal fibroblasts. | Neuro Oncol. 2011 Nov;13(11):1213-24 |
| Primary GBM cells | 0.25 μM | 48 hours | Lanatoside C significantly reduces the viability of primary GBM cells and enhances sensitivity to TRAIL. | Neuro Oncol. 2011 Nov;13(11):1213-24 |
| U87 cells | 0.25 μM and 1 μM | 16 hours | Lanatoside C upregulates DR5 expression, enhancing GBM cell sensitivity to TRAIL-induced cell death. | Neuro Oncol. 2011 Nov;13(11):1213-24 |
| human brain endothelial cells | 10 µM | 24 hours | Lanatoside C blocked IL-1β-induced inflammatory secretions including CCL2, sICAM-1, sVCAM-1, IL-6, IL-8, CX3CL1, RANTES, G-CSF, and GM-CSF | Commun Biol. 2021 Feb 26;4(1):260 |
| EL4 cells | 2 μM | 6 hours | Lanatoside C significantly downregulated RUNX1 protein level | EMBO Mol Med. 2025 Mar;17(3):563-588 |
| MCF-7 | 1 μM or 5 μM | 24 hours | LanC suppressed the increase in GRP78 expression induced by Tg | Neoplasia. 2021 Dec;23(12):1213-1226 |
| SK-MEL-28 | 1 μM or 5 μM | 24 hours | LanC suppressed the increase in GRP78 expression induced by Tg | Neoplasia. 2021 Dec;23(12):1213-1226 |
| HeLa | 1 μM or 5 μM | 24 hours | LanC suppressed the increase in GRP78 expression induced by Tg | Neoplasia. 2021 Dec;23(12):1213-1226 |
| SCC-25 | 1 μM or 5 μM | 24 hours | LanC suppressed the increase in GRP78 expression induced by Tg | Neoplasia. 2021 Dec;23(12):1213-1226 |
| A549 | 1 μM or 5 μM | 24 hours | LanC suppressed the increase in GRP78 expression induced by Tg | Neoplasia. 2021 Dec;23(12):1213-1226 |
| CFPAC-1 | 1 μM | 24 hours | LanC suppressed the increase in GRP78 expression induced by Tg, Tu, or 2-DG | Neoplasia. 2021 Dec;23(12):1213-1226 |
| PANC-1 | 1 μM | 24 hours | LanC suppressed the increase in GRP78 expression induced by Tg, Tu, or 2-DG, bringing its level close to that of untreated cells | Neoplasia. 2021 Dec;23(12):1213-1226 |
| GBM8 neural sphere cells | 0.25 μM | 24 hours | To evaluate the effect of Lanatoside C combined with sTRAIL on the viability of GBM8 neural sphere cells. Results showed that GBM8 neural sphere cells were more sensitive to sTRAIL and Lanatoside C alone, and the combination treatment resulted in a significant decrease in cell viability (around 90%). | Mol Oncol. 2016 Apr;10(4):625-34 |
| U87 human glioblastoma cells | 0.25 μM | 24 hours | To evaluate the effect of Lanatoside C combined with sTRAIL on the viability of U87 cells. Results showed that sTRAIL alone did not cause cell death, while 0.25 μM Lanatoside C alone caused approximately 50% cell death. The combination of sTRAIL and Lanatoside C resulted in a significant decrease in cell viability (around 80%). | Mol Oncol. 2016 Apr;10(4):625-34 |
| 293T-NF+RC cells | 10 μM | 30 minutes | Lanatoside C potently inhibited the interaction between FOXP3 and RUNX1 | EMBO Mol Med. 2025 Mar;17(3):563-588 |
| human brain pericytes | 10 µM | 24 hours | Screening for compounds that modulate IL-1β-induced CCL2 and ICAM-1 expression, Lanatoside C showed anti-inflammatory effects | Commun Biol. 2021 Feb 26;4(1):260 |
| Administration | Dosage | Frequency | Description | References | ||
| Nude mice | U87-Gluc-CFP subcutaneous xenograft model | Intraperitoneal injection | 6 mg/kg body weight | Once daily for 10 days | Lanatoside C alone or in combination with TRAIL significantly inhibits tumor growth, with combination therapy reducing tumor volume by more than 85%. | Neuro Oncol. 2011 Nov;13(11):1213-24 |
| BALB/c nude mice | DLBCL xenograft model | Intraperitoneal injection | 6 mg/kg | Every two days until the end of the experiment | To evaluate the inhibitory effect of Lanatoside C on DLBCL tumor growth | Leukemia. 2024 Feb;38(2):351-364 |
| Athymic nude mice | Intracranial U87 glioblastoma model | Intraperitoneal injection | 7.5 mg/kg | Once daily for 5 days | To evaluate the effect of Lanatoside C combined with AAV-sTRAIL on intracranial U87 tumors. Results showed that Lanatoside C treatment led to a significant decrease in tumor-associated Fluc signal, and tumors regrew rapidly after stopping treatment. Re-administration of Lanatoside C re-sensitized tumors to sTRAIL-induced cell death. The combination therapy significantly slowed tumor growth and prolonged mouse survival. | Mol Oncol. 2016 Apr;10(4):625-34 |
| C57BL/6J mice | LLC allograft tumor model | Intraperitoneal injection (IP) | 6 mg/kg | Every 2 days for 2 weeks | Lanatoside C significantly inhibited the growth of LLC tumors | EMBO Mol Med. 2025 Mar;17(3):563-588 |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
1.02mL 0.20mL 0.10mL |
5.08mL 1.02mL 0.51mL |
10.15mL 2.03mL 1.02mL |
|
| CAS号 | 17575-22-3 |
| 分子式 | C49H76O20 |
| 分子量 | 985.12 |
| SMILES Code | O[C@]([C@@](CC[C@@]1([H])[C@@]2(CC[C@H](O[C@@](O[C@H](C)[C@H]3O[C@@](O[C@H](C)[C@H]4O[C@@](O[C@H](C)[C@H]5O[C@]([C@@H]([C@@H](O)[C@@H]6O)O)([H])O[C@@H]6CO)([H])C[C@@H]5OC(C)=O)([H])C[C@@H]4O)([H])C[C@@H]3O)C1)C)([H])[C@]2([H])C[C@H]7O)(CC[C@@H]8C(CO9)=CC9=O)[C@]78C |
| MDL No. | MFCD00869432 |
| 别名 | 毛花苷C |
| 运输 | 蓝冰 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, store in freezer, under -20°C |
| 溶解方案 |
DMSO: 50 mg/mL(50.76 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 无水乙醇: 2 mg/mL(2.03 mM),配合低频超声助溶,注意:无水乙醇开封后,易挥发,也会吸收空气中的水分,导致溶解能力下降,请避免使用开封较久的乙醇 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1